Theravance Biopharma Inc. (TBPH)
9.15
-0.20 (-2.14%)
At close: Mar 03, 2025, 3:59 PM
9.15
0.00%
After-hours: Mar 03, 2025, 04:00 PM EST
Theravance Biopharma Inc. Revenue Breakdown
| Quarter | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Collaboration revenue Revenue | 16.87M | 14.5M | 21.23M | 19.3M | 6K | 5K | 18.7M | 17.2M | 15.3M |
| Collaboration revenue Revenue Growth | +16.31% | -31.67% | +9.97% | +321566.67% | +20.00% | -99.97% | +8.72% | +12.42% | n/a |
| YUPELRI Monotherapy Revenue | 21.77M | 19.33M | n/a | 6K | 16.4M | n/a | 6K | n/a | n/a |
| YUPELRI Monotherapy Revenue Growth | +12.61% | n/a | n/a | -99.96% | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Quarter | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Europe Revenue | 223K | 222K | 38K | 1.54M | 18.65M | 11.12M | 1.11M | 15.21M | 21.35M |
| Europe Revenue Growth | +0.45% | +484.21% | -97.53% | -91.76% | +67.80% | +902.43% | -92.71% | -28.77% | n/a |
| United States Revenue | 57.2M | 51.12M | 55.27M | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue Growth | +11.89% | -7.51% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 16.88M | 17.06M | 15.64M | 15.49M | 16.14M | 19.28M | 19.18M | 16.73M | 16.28M | 16.99M | 23.64M | 21.52M | 21.3M | 25.93M | 30.55M | 30.05M | 27.5M | 24.78M | 26.32M | 33.05M | 25.62M | 22.23M | 25.19M | 25.46M | 21.89M | 25.01M | 24.7M | 29.52M | 20.94M | 24.34M | 20.79M | 20.37M | 20.29M | 20.26M | 23.6M | 24.06M | 22.84M | 21.55M | 21.75M |
| Selling, General, and Administrative Revenue Growth | -1.06% | +9.05% | +0.96% | -4.03% | -16.27% | +0.50% | +14.63% | +2.81% | -4.17% | -28.14% | +9.86% | +1.02% | -17.86% | -15.12% | +1.65% | +9.29% | +10.98% | -5.87% | -20.34% | +28.98% | +15.27% | -11.75% | -1.06% | +16.30% | -12.46% | +1.23% | -16.33% | +40.97% | -13.95% | +17.09% | +2.06% | +0.39% | +0.12% | -14.13% | -1.94% | +5.34% | +6.03% | -0.93% | n/a |
| Research and Development Revenue | 9.27M | 9.95M | 8.54M | 8.31M | 8.31M | 9.43M | 14.57M | 15.35M | 9.87M | 15.57M | 23.25M | 31.23M | 43.74M | 51.09M | 67.6M | 65.17M | 67.37M | 62.4M | 66.01M | 67.03M | 52.01M | 46.4M | 53.82M | 52.27M | 52.69M | 48.62M | 47.77M | 51.05M | 39.34M | 42.93M | 40.56M | 42.01M | 31.95M | 32.07M | 35.68M | 32.4M | 30.37M | 30.38M | 36.02M |
| Research and Development Revenue Growth | -6.89% | +16.61% | +2.67% | +0.04% | -11.82% | -35.32% | -5.05% | +55.54% | -36.63% | -33.04% | -25.53% | -28.61% | -14.39% | -24.42% | +3.74% | -3.27% | +7.96% | -5.47% | -1.51% | +28.88% | +12.08% | -13.79% | +2.96% | -0.80% | +8.37% | +1.79% | -6.44% | +29.76% | -8.35% | +5.82% | -3.45% | +31.49% | -0.37% | -10.12% | +10.11% | +6.70% | -0.03% | -15.66% | n/a |